RATIONALE: Glutamatergic abnormalities are involved in the etiology of schizophrenia. Clinical evidence demonstrates that positive modulation of "glycine modulatory sites" on N-methyl-D: -aspartic acid (NMDA) receptors improve cognitive deficits as well as positive and negative symptoms in schizophrenic patients. OBJECTIVES: In the present study, we investigated the effects of positive modulation of glycine sites on the NMDA receptor using an agonist of the glycine modulatory site, D: -serine, and a glycine transporter-1 inhibitor, (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (NFPS). In particular, we focused on the effects on cognitive functioning using social recognition test in rats. We then compared these effects with those of an atypical antipsychotic clozapine and a typical antipsychotic haloperidol. RESULTS: Both D: -serine and NFPS significantly enhanced social memory in naïve rats, as did clozapine, while the typical antipsychotic haloperidol was ineffective. A noncompetitive NMDA receptor antagonist, MK-801, significantly impaired social memory, which was significantly attenuated by pretreatment with clozapine, but not with haloperidol. Likewise, NFPS significantly improved MK-801-disrupted cognition in the social recognition test. None of these drugs affected social interaction time. CONCLUSIONS: The present results show that stimulation of the glycine modulatory sites on the NMDA receptor either directly with D: -serine or by blocking glycine transporter-1 enhances social memory and may be an effective approach for the treatment of the cognitive dysfunction observed in schizophrenic patients.
RATIONALE: Glutamatergic abnormalities are involved in the etiology of schizophrenia. Clinical evidence demonstrates that positive modulation of "glycine modulatory sites" on N-methyl-D: -aspartic acid (NMDA) receptors improve cognitive deficits as well as positive and negative symptoms in schizophrenicpatients. OBJECTIVES: In the present study, we investigated the effects of positive modulation of glycine sites on the NMDA receptor using an agonist of the glycine modulatory site, D: -serine, and a glycine transporter-1 inhibitor, (R)-(N-[3-(4'-fluorophenyl)-3-(4'-phenylphenoxy)propyl])sarcosine (NFPS). In particular, we focused on the effects on cognitive functioning using social recognition test in rats. We then compared these effects with those of an atypical antipsychotic clozapine and a typical antipsychotic haloperidol. RESULTS: Both D: -serine and NFPS significantly enhanced social memory in naïve rats, as did clozapine, while the typical antipsychotic haloperidol was ineffective. A noncompetitive NMDA receptor antagonist, MK-801, significantly impaired social memory, which was significantly attenuated by pretreatment with clozapine, but not with haloperidol. Likewise, NFPS significantly improved MK-801-disrupted cognition in the social recognition test. None of these drugs affected social interaction time. CONCLUSIONS: The present results show that stimulation of the glycine modulatory sites on the NMDA receptor either directly with D: -serine or by blocking glycine transporter-1 enhances social memory and may be an effective approach for the treatment of the cognitive dysfunction observed in schizophrenicpatients.
Authors: John H Krystal; D Cyril D'Souza; Daniel Mathalon; Edward Perry; Aysenil Belger; Ralph Hoffman Journal: Psychopharmacology (Berl) Date: 2003-09-02 Impact factor: 4.530
Authors: Gerard B Fox; Timothy A Esbenshade; Jia Bao Pan; Richard J Radek; Kathleen M Krueger; Betty B Yao; Kaitlin E Browman; Michael J Buckley; Michael E Ballard; Victoria A Komater; Holly Miner; Min Zhang; Ramin Faghih; Lynne E Rueter; R Scott Bitner; Karla U Drescher; Jill Wetter; Kennan Marsh; Martine Lemaire; Roger D Porsolt; Youssef L Bennani; James P Sullivan; Marlon D Cowart; Michael W Decker; Arthur A Hancock Journal: J Pharmacol Exp Ther Date: 2004-12-17 Impact factor: 4.030
Authors: Kwang-Hyuk Lee; Wendy H Brown; Paul N Egleston; Russell D J Green; Tom F D Farrow; Michael D Hunter; Randolph W Parks; Iain D Wilkinson; Sean A Spence; Peter W R Woodruff Journal: Am J Psychiatry Date: 2006-11 Impact factor: 18.112
Authors: David J G Watson; Florence Loiseau; Manuela Ingallinesi; Mark J Millan; Charles A Marsden; Kevin C F Fone Journal: Neuropsychopharmacology Date: 2011-10-26 Impact factor: 7.853
Authors: Patricia Bado; Caroline Madeira; Charles Vargas-Lopes; Thiago C Moulin; Ana Paula Wasilewska-Sampaio; Luise Maretti; Ricardo V de Oliveira; Olavo B Amaral; Rogério Panizzutti Journal: Psychopharmacology (Berl) Date: 2011-05-10 Impact factor: 4.530
Authors: Kathleen M Kantak; Jamie M Gauthier; Elon Mathieson; Eudokia Knyazhanskaya; Pedro Rodriguez-Echemendia; Heng-Ye Man Journal: Behav Brain Res Date: 2020-08-02 Impact factor: 3.332
Authors: Kirsten C Svane; Ericka-Kate Asis; Anton Omelchenko; Ansley J Kunnath; Linda M Brzustowicz; Steven M Silverstein; Bonnie L Firestein Journal: Mol Cell Neurosci Date: 2018-03-27 Impact factor: 4.314